A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma
A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma
- Disease:Follicle centre lymphoma follicular grade I, II - III
- Substances:CyclophosphamideOdronextamab+5
Poland- Participants:18–64 years · 65+ years
- Substances:Cyclophosphamide
- Sponsor:Regeneron Pharmaceuticals Inc.











